Rellme David, Shah Kamran, Ekelund Mikael, Gislason Hjörtur
Metabolic and Bariatric Unit, GB Obesitas, Malmö, Sweden.
Skåne University Hospital, Lund & Malmö, Sweden.
Obes Surg. 2025 Apr;35(4):1484-1492. doi: 10.1007/s11695-025-07796-7. Epub 2025 Mar 15.
A limited subset of patients undergoing Roux-en-Y gastric bypass (RYGB) may develop intractable symptoms that ultimately require reversal to normal anatomy. Existing literature on this subject is characterized by small cohort sizes, substantial variation in surgical techniques, and limited follow-up durations. However, this study presents the largest single-center series to date, comprising seventy patients.
A prospective analysis was conducted on clinical data from patients who underwent laparoscopic reversal of Roux-en-Y gastric bypass (RYGB). The study evaluated the indications for the procedure, technical considerations, clinical outcomes, and associated complications. Patients were stratified into two groups based on their primary symptoms: Group 1 (abdominal pain; n = 47) and Group 2 (hypoglycemia, malnutrition, or other symptoms; n = 23).
Seventy patients were included in the study, with a mean follow-up period of 2.4 years. The majority of patients (93%, 65/70) were female, and the mean age was 44 ± 11.45 years. The mean body mass index (BMI) at baseline was 28.7 ± 6.3 kg/m. In Group 1, 85% of patients experienced either complete or partial resolution of symptoms, while in Group 2, 96% achieved complete symptom resolution. Thromboembolic complications occurred in 7.1% of patients, and 13% required reoperation. At 12 months post-reversal, mean weight and BMI had increased by 9.1 kg and 3.2 kg/m, respectively. At the most recent follow-up, the total weight gain (Δkg) was 14.9 kg, and the BMI increase (ΔBMI) was 5.1 kg/m.
Reversal of Roux-en-Y gastric bypass (RYGB) is an effective intervention for patients experiencing chronic complications. Patients with hypoglycemia and malnutrition experienced higher rates of symptom resolution compared to those with abdominal pain or small bowel adhesions. The implementation of pyloroplasty, combined with high-dose subcutaneous anticoagulant therapy, was associated with a reduction in complication rates. Given the expected weight regain following reversal, it is essential for both surgeons and patients to align their expectations with anticipated outcomes.
接受Roux-en-Y胃旁路术(RYGB)的一小部分患者可能会出现顽固性症状,最终需要恢复正常解剖结构。关于这一主题的现有文献存在样本量小、手术技术差异大以及随访时间有限的特点。然而,本研究呈现了迄今为止最大的单中心系列病例,共纳入70例患者。
对接受腹腔镜下Roux-en-Y胃旁路术(RYGB)逆转手术患者的临床数据进行前瞻性分析。该研究评估了手术指征、技术要点、临床结局及相关并发症。根据患者的主要症状将其分为两组:第1组(腹痛;n = 47)和第2组(低血糖、营养不良或其他症状;n = 23)。
70例患者纳入研究,平均随访时间为2.4年。大多数患者(93%,65/70)为女性,平均年龄为44 ± 11.45岁。基线时平均体重指数(BMI)为28.7 ± 6.3 kg/m²。在第1组中,85%的患者症状完全或部分缓解,而在第2组中,96%的患者症状完全缓解。7.1%的患者发生血栓栓塞并发症,13%的患者需要再次手术。逆转术后12个月,平均体重和BMI分别增加了9.1 kg和3.2 kg/m²。在最近一次随访时,总体重增加量(Δkg)为14.9 kg,BMI增加量(ΔBMI)为5.1 kg/m²。
Roux-en-Y胃旁路术(RYGB)逆转术是治疗慢性并发症患者的有效干预措施。与腹痛或小肠粘连患者相比,低血糖和营养不良患者的症状缓解率更高。实施幽门成形术并联合大剂量皮下抗凝治疗与并发症发生率降低相关。鉴于逆转术后预期的体重增加,外科医生和患者都必须使他们的期望与预期结果相一致。